Thousands of Madhya Pradesh Government Doctors Protest Arrest of Paediatrician in Toxic Cough Syrup Deaths Case, Demand Justice and Regulatory Reform

Spread the Message

Read Time:4 Minute, 4 Second

In Madhya Pradesh, over 8,500 government doctors staged a peaceful protest against the arrest of Dr. Praveen Soni, a paediatrician implicated in the tragic deaths of at least 22 children linked to consumption of a contaminated cough syrup, Coldrif. The protest took place in October 2025, with the medical community alleging that Dr. Soni was scapegoated for a regulatory failure that allowed toxic industrial solvents into pharmaceutical products sold to vulnerable populations. The doctors called for accountability to be directed at manufacturers of adulterated medicines, not prescribing physicians, amidst a crisis that has spotlighted systemic gaps in drug regulation and safety.

Key Findings and Developments

The controversy centers around Coldrif cough syrup, manufactured by Sresan Pharmaceuticals, which was found to contain dangerously high levels of diethylene glycol (DEG), an industrial solvent toxic to humans. Laboratory tests confirmed DEG concentrations nearly 500 times above permissible limits in syrup samples, linking the substance directly to the kidney failure that caused multiple child fatalities in Madhya Pradesh and neighboring states.

Dr. Praveen Soni, a government paediatrician in Chhindwara district, was arrested on allegations of criminal negligence for prescribing Coldrif syrup to children, including poor tribal populations, where the syrup’s low cost (around Rs 30 per bottle) made it a widely used medicine for respiratory illnesses. The arrest triggered outrage among medical professionals nationwide, who argued that criminal liability for such deaths lies squarely with manufacturers and regulators responsible for ensuring drug safety, not individual doctors who prescribed legally approved medicines.

Expert Perspectives

Dr. Rakesh Malviya, president of the Progressive Medical Teachers Association of Madhya Pradesh (PMTAMP), emphasized that Dr. Soni prescribed the syrup considering the economic hardships of patients in tribal regions, highlighting that the contaminated syrup had been in use for over 30 years. He criticized the lack of regulatory oversight allowing toxic medicines to enter the market, advocating for stringent action against the manufacturers rather than penalizing frontline medical practitioners.

Dr. Neelam Mohan, National President-Elect of the Indian Academy of Paediatrics (IAP) and Senior Director at Medanta Hospital, described the incident as a “systemic regulatory collapse” instead of negligent prescribing. She underscored that the presence of toxic DEG pointed to severe adulteration at the manufacturing stage, not a fault in the prescription process, warning that criminalizing doctors could foster fear and hamper healthcare delivery in underserved areas.

Context and Background Information

Diethylene glycol (DEG) is a colorless, odorless, sweet-tasting industrial chemical used in antifreeze and plastics, highly toxic if ingested. It damages the kidneys and nervous system, causing acute kidney failure, seizures, and death, especially in children who are more vulnerable to its effects. DEG poisoning symptoms often manifest after a delay, complicating early detection and treatment.

India has a tragic history of fatalities from DEG-contaminated medicines. Over the years, similar outbreaks have caused child deaths in various states, exposing a fragmented pharmaceutical market with gaps in quality control and enforcement. The World Health Organization (WHO) flagged India’s regulatory system after these incidents, emphasizing urgent reforms to prevent further poisonings.

Implications for Public Health

This case highlights critical challenges in pharmaceutical surveillance, regulatory enforcement, and healthcare equity. Affordable medicines are essential for low-income communities, yet this tragedy underscores the lethal consequences when safety is compromised. Strengthening quality assurance of medicines, fast-tracking recall procedures, and empowering regulators are essential steps to protect vulnerable populations. The medical community’s unified response also stresses the need to shield frontline healthcare workers from punitive actions when they prescribe approved medicines in good faith.

Potential Limitations and Counterarguments

Authorities have noted serious evidence linking Dr. Soni to negligence, which led to his arrest, and courts have denied his bail, indicating an ongoing judicial examination. Calls for accountability extend beyond manufacturers to any parties involved, underscoring legal complexities in public health crises. Nonetheless, expert groups caution that disproportionate blame on individual doctors risks deterring medical professionals from serving high-need populations or undermining trust in healthcare.

Practical Implications for Readers

Consumers should be aware of the critical importance of medicine safety and the risks associated with unregulated pharmaceutical products. It is advisable to procure medicines from trusted sources and consult licensed health professionals for treatment decisions. Policymakers and health authorities must ensure transparent communication and rapid action in incidents of drug contamination to maintain public confidence and prevent avoidable tragedies.

Medical Disclaimer

This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.